Average Insider

Where insiders trade, we follow

$SHPH
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Christopher Robert Cooper
CEO
9
Employees
$3.56
Current Price
$2.07M
Market Cap
52W Low$2.90
Current$3.561.2% above low, 98.8% below high
52W High$55.90

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys13$123,759.1936,550All Buys
Sells00--
2 weeksBuys13$123,759.1936,550All Buys
Sells00--
1 monthBuys13$123,759.1936,550All Buys
Sells00--
2 monthsBuys13$123,759.1936,550All Buys
Sells00--
3 monthsBuys13$123,759.1936,550All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 1, 2026
HRT FINANCIAL LP
10% Owner
Purchase3,959$3.30$13,064.70View Details
Jun 29, 2026
HRT FINANCIAL LP
10% Owner
Purchase25,836$3.44$88,875.84View Details
Jun 30, 2026
HRT FINANCIAL LP
10% Owner
Purchase6,755$3.23$21,818.65View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.5.2